Complete Conference Coverage
Researchers observed increased real-world incidence of cardiomyopathy in patients treated with trabectedin compared with that seen in the phase 3 study of the drug.
Australian researchers identified the gene using whole-genome sequencing in patients enrolled in the International Sarcoma Kindred Study.
But, there was no difference in DFS, DMFS, or OS between the 2 treatment subtypes at 5 years following the conclusion of the original study.
The switch from a continuous to an intermittent dosing schedule appeared to cut the occurrence of thrombocytopenia in half.
A subset of patients experienced sustained clinical benefit and at least some objective tumor response.
Researchers suggested the use of comparative oncology to identify novel therapies that could have clinical applications in osteosarcoma.
Analysis of transcriptomic data revealed that a subset of patients with these smooth muscle sarcomas have ALK fusions that retain targetable ALK kinase domains.
Patients with fascia-infiltrating sarcoma appeared to have worse survival that those who had either strict superficial or deep soft tissue sarcomas.
Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.
Pembrolizumab monotherapy and pembrolizumab plus chemotherapy prolonged OS in recurrent/metastatic HNSCC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
- Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited
- POT1 Revealed as a Sarcoma Predisposition Gene
- IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up
- Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors
- Palliative Care and Survivorship